MYO MYOMO, INC.

CIK 0001369290 50 ready 8-Ks latest June 29, 2026, 9:06 AM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing June 29, 2026, 9:06 AM ET

Top materiality 0.85

Event mix earnings ×19 · other_material ×16 · regulatory ×6

Sentiment 21 pos · 4 neg · 25 neu

Latest earnings ▲ beat 2026-Q1

Executive change recent →

Recent 8-K filings for MYO

Highest-materiality recent filing

Myomo Q2 revenue $9.7M (+28%) but operating loss widens; cuts FY2025 guidance to $40-42M

August 11, 2025, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

Revenue $9.7M (+28% YoY), revenue units 178 (+13%), ASP ~$54,200 (+14%).
Orders/authorizations 207 (-3%), backlog 230 units (-18%), pipeline adds 816 (+49%).

Read filing →

June 29, 2026, 9:06 AM ET other material materiality 0.55 neutral item 5.02 item 5.03 item 5.07 item 9.01

Myomo stockholders vote to increase authorized shares to 100M and expand stock plan by 1.83M shares

Stockholders approved charter amendment increasing authorized common shares to 100,000,000.
June 26, 2026, 4:05 PM ET other material materiality 0.45 neutral item 5.02 item 5.07 item 5.03 item 9.01

Myomo shareholders approve 100M authorized shares and 1.833M share plan increase

Elected Paul R. Gudonis and Thomas F. Kirk as Class III directors to three-year terms expiring 2029.
May 13, 2026, 4:10 PM ET leadership materiality 0.40 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Myomo appoints Joseph Manko Jr., founder of Horton Capital, as director

Joseph M. Manko Jr. appointed as Class I director effective May 9, 2026, through 2027 annual meeting.
May 7, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Myomo Q1 revenue $10.1M (+3% YoY); net loss narrows to $3.0M; guides Q2 $10.3M-$10.8M

Revenue $10.1M (+3% YoY), net loss $3.0M ($0.07/sh) vs $3.5M loss ($0.08/sh) in Q1 2025.
April 16, 2026, 7:59 PM ET leadership materiality 0.45 neutral item 5.02 item 7.01 item 9.01

Myomo appoints William J. Febbo to Board, effective April 14, 2026

Febbo, 57, is CEO of Performance Health Systems and former CEO of OptimizeRx (OPRX), where he grew revenue from $5M to $92M.
March 9, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Myomo Q4 revenue falls 6% to $11.4M; net loss widens to $3.8M

Q4 revenue $11.4M (-6% YoY); full year $40.9M (+26% YoY).
December 16, 2025, 6:59 PM ET other material materiality 0.20 positive item 5.02 item 9.01

Myomo CEO & CFO take 10% salary cut in 2026, receiving RSUs at 115% of foregone amount

CEO Paul Gudonis voluntarily reduces 2026 base salary 10% ($40,000) for RSUs worth $46,000 (115% of foregone).
November 10, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 1.01 item 2.02 item 2.03 item 3.02 item 9.01 ◈ Debt Financings◈ Equity Issuances

Myomo Q3 revenue $10.1M (+10% YoY); net loss $0.09/shr; FY guidance $40-42M

Revenue $10.1M, up 10% YoY; 186 units sold (+16%), ASP ~$54,200 (-5%).
August 11, 2025, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

Myomo Q2 revenue $9.7M (+28%) but operating loss widens; cuts FY2025 guidance to $40-42M

Revenue $9.7M (+28% YoY), revenue units 178 (+13%), ASP ~$54,200 (+14%).
June 18, 2025, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

Myomo sets 2028 revenue target of $100M, gross margin 70-72% at Investor Day

Aspirational goal of $100M annual revenue by 2028, including $15M international and $20M O&P channel revenue.
June 13, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

Myomo stockholders elect Heather Getz as Class II director, ratify CBIZ as auditor for FY2025

Heather Getz elected as Class II director for three-year term expiring at 2028 annual meeting; 10,294,384 for, 1,888,001 withheld, 12,131,966 broker non-votes.
May 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Myomo Q1 revenue $9.8M (+162%); record 700 pipeline adds; guides Q2 $9.0-9.5M

Revenue $9.8M (+162% YoY) on 182 units (+100%); gross margin 67.2% (up 600 bps).
April 10, 2025, 7:59 PM ET other material materiality 0.60 neutral item 4.01 item 5.02 item 7.01 item 9.01 ◈ Auditor Changes ×2◈ executive_change ×2

Myomo names CBIZ as new auditor; two directors exit board

Marcum LLP resigned as auditor April 8; CBIZ CPAs engaged after acquiring Marcum's attest business.
March 10, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Myomo Q4 revenue $12.1M record, first positive op. cash flow; guides FY2025 $50-53M

Q4 revenue $12.1M (+154% YoY); 220 units shipped (+106%); ASP ~$54,900 (+23%).
February 20, 2025, 6:59 PM ET debt materiality 0.50 neutral item 1.01 item 2.04 item 2.03 item 9.01

Myomo enters $3M term loan with SVB; revises revolver Medicare concentration limit

New $3M term loan available until Feb 28, 2026; repayable in 36 monthly installments from Mar 1, 2026, maturing Feb 1, 2029.
December 5, 2024, 6:59 PM ET other material materiality 0.70 neutral item 1.01 item 8.01 item 9.01

Myomo prices $15M public offering of 3M shares at $5.00; underwriter option exercised in full

3,000,000 shares priced at $5.00 each; gross proceeds of $15.0M expected before expenses.
November 6, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Myomo Q3 revenue record $9.2M (+81% YoY); FY guidance raised to $30-31M

Record Q3 product revenue $9.2M, +83% YoY; net loss $1.0M ($0.03/sh) vs $2.0M loss year ago.
August 13, 2024, 7:59 PM ET other material materiality 0.75 positive item 1.01 item 2.03 item 9.01

Myomo signs 88-month lease for 36,208 sq ft in Burlington, MA for HQ and manufacturing

Lease for approx. 36,208 rentable sq ft at 45 Blue Sky Drive; monthly rent starts at $96,250 and escalates over 8-year term.
August 6, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Myomo Q2 2024 revenue $7.5M (+77% product revenue); record 213 MyoPro orders

Product revenue $7.5M (+77% YoY); total revenue $7.5M (+26% YoY) reflecting prior-year license fee.
July 15, 2024, 7:59 PM ET debt materiality 0.65 neutral item 1.01 item 2.03 item 9.01

Myomo enters $4M revolving credit facility with Silicon Valley Bank

Revolver up to $4M (expandable to $5.5M); interest rate greater of 8.50% or prime + 0.50%.
July 8, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Myomo expects record Q2 revenue $7.2M-$7.4M, up 92-97% sequentially

Preliminary Q2 revenue $7.2M-$7.4M, 92-97% sequential increase, highest ever.
June 7, 2024, 7:59 PM ET other material materiality 0.00 neutral item 5.07

Myomo shareholders elect Crowley and Morris as Class I directors, ratify Marcum as auditor

Thomas A. Crowley received 9,246,482 votes for, 1,049,041 withheld, and 11,747,021 broker non-votes.
May 8, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Myomo Q1 revenue $3.8M (+9% YoY); backlog record 275 units; net loss $3.8M

Revenue $3.8M (+9% YoY); product revenue $3.75M; revenue units 91 (+14%).
May 6, 2024, 7:59 PM ET regulatory materiality 0.65 positive item 8.01 item 9.01

Myomo receives first lump sum Medicare reimbursements for MyoPro under new CMS fees

CMS through DME MACs remitted lump sum reimbursements for MyoPros to Medicare Part B beneficiaries.
March 28, 2024, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Myomo appoints Heather Getz to board as director and audit committee chair

Board increased from 6 to 7 members; Ms. Getz appointed as Class II director effective March 26, 2024.
March 7, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Myomo Q4 revenue $4.8M (+18% YoY), backlog record 230 units, guides FY2024 rev $28M-$30M

Q4 product revenue $4.756M (+18% YoY); recognized 107 MyoPro units (+6%).
March 1, 2024, 6:59 PM ET regulatory materiality 0.70 positive item 8.01 item 9.01

CMS finalizes Medicare fee schedule for Myomo's MyoPro at $33,481-$65,872 per device

CMS final fee schedule rates: L8701 (Motion W) $33,480.90, L8702 (Motion G) $65,871.74, effective April 1, 2024.
February 22, 2024, 6:59 PM ET other material materiality 0.40 neutral item 5.02 item 9.01

Myomo amends CFO Henry's salary to $260K; CMO Kovelman gets new severance terms

CFO David Henry: base salary raised from $221,500 to $260,000; annual incentive cap reduced from 75% to 55% of base.
January 17, 2024, 6:59 PM ET earnings materiality 0.80 positive item 1.01 item 2.02 item 8.01 item 9.01 ◈ Earnings Releases◈ Material Agreements

Myomo reports prelim Q4 revenue $4.6-$4.8M (+14-19% YoY), raises $6M in registered direct offering

Preliminary Q4 2023 revenue expected $4.6-$4.8M, up 14-19% YoY; cash $8.7M at Dec 31, 2023.
December 19, 2023, 6:59 PM ET leadership materiality 0.40 neutral item 5.02

Myomo renews CEO Paul Gudonis employment agreement; $350K base salary, term through Dec 2026

Base salary of $350,000 with annual bonus opportunity up to 75% of base, effective Jan 1, 2024.
November 7, 2023, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

Myomo Q3 record product revenue $5.0M, up 27% YoY; net loss narrows to $2.0M

Total revenue $5.1M (+28% YoY); product revenue $5.0M (+27%) on 119 units (+37%).
November 6, 2023, 6:59 PM ET regulatory materiality 0.65 positive item 8.01 item 9.01

CMS proposes Medicare reimbursement rates for MyoPro: $31,745 for L8701, $62,457 for L8702

CMS proposed fee schedule rates: L8701 (Motion W) at $31,745.42 and L8702 (Motion G) at $62,457.28.
November 2, 2023, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

CMS classifies MyoPro as Medicare Part B brace, lump-sum reimbursement from Jan 1, 2024

CMS final rule published Nov 1, effective Jan 1, 2024: MyoPro classified as a brace, paid lump sum.
August 28, 2023, 7:59 PM ET other material materiality 0.65 neutral item 1.01 item 9.01

Myomo raises $4.4M in registered public offering of common stock and pre-funded warrants

Offering consists of 5,413,334 shares of common stock and 1,920,000 pre-funded warrants at $0.60 per share/$0.5999 per warrant.
August 24, 2023, 7:59 PM ET regulatory materiality 0.75 positive item 1.02 item 8.01 item 9.01 ◈ Material Agreements

Myomo receives first Medicare Part B payments for MyoPro; terminates Keystone stock agreement

Received payment on two MyoPro claims under Medicare Part B capped rental program (13-month payout).
August 9, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Myomo Q2 revenue up 62% to $6.0M; net loss narrows to $1.0M

Product revenue $4.2M (+15% YoY); revenue units 97 (+21%). Total revenue includes $1.7M JV license fee.
June 9, 2023, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×5

Myomo stockholders re-elect 2 directors, approve 1.1M share plan increase, say-on-pay every 3 years

Paul R. Gudonis and Thomas F. Kirk re-elected as Class III directors through 2026 annual meeting.
May 10, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Myomo Q1 product rev up 20% to $3.4M; record 438 pipeline patients added

Product revenue $3.4M, +20% YoY; total revenue $3.4M (-11% due to prior-year license fee).
April 10, 2023, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Myomo receives $1.7M final license fee from China JV, enabling MyoPro manufacturing and sales in China

Received final $1.7M of initial license fee from Jiangxi Myomo JV; total upfront fee now $2.7M.
March 13, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Myomo Q4 revenue flat at $4.0M; net loss improves to $0.29/share

Q4 product revenue $4.0M, flat YoY and up 2% sequentially; 101 units (down 6% YoY).
January 30, 2023, 6:59 PM ET leadership materiality 0.30 neutral item 5.02 item 9.01 ◈ executive_change

Myomo appoints Yitzchak Jacobovitz to board of directors

Board expanded from five to six members; Jacobovitz appointed Class II director effective Jan 27, 2023.
January 13, 2023, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01 ◈ Material Agreements ×2

Myomo raises $6.5M in registered offering of 13.17M shares and pre-funded warrants at $0.325

Gross proceeds of $6.5M from sale of 13,169,074 shares at $0.325 and pre-funded warrants for 6,830,926 shares at $0.3249.
January 10, 2023, 6:59 PM ET other material materiality 0.55 neutral item 8.01 item 9.01

Myomo reduces workforce by 12% to cut annual expenses by $2M

Workforce reduction of 12%, primarily affecting call center and administrative staff.
December 7, 2022, 6:59 PM ET other material materiality 0.65 negative item 8.01

Myomo fails to convene special meeting to approve Keystone stock issuance; withdraws proposals

Special meeting on Dec 7, 2022 lacked quorum; only majority of proxies received were in favor.
November 10, 2022, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Myomo reports Q3 product revenue $4.0M, up 8% sequentially; record backlog of 184 units

Product revenue $4.0M, down 9% YoY but up 8% sequentially; revenue units 87, down 15% YoY.
September 27, 2022, 7:59 PM ET regulatory materiality 0.65 negative item 8.01

CMS defers Myomo's request to reclassify MyoPro as brace; decision expected Q1 2023

CMS declined to rule on Myomo's request to reclassify MyoPro from rental DME to lump-sum brace.
August 3, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Myomo Q2 revenue up 18% to $3.7M; record pipeline adds 52% YoY; net loss widens to $0.42/share

Revenue $3.7M (+18% YoY, +28% seq); product units 80, flat YoY; ASP up via direct billing (83% of revenue).
August 2, 2022, 7:59 PM ET other material materiality 0.55 neutral item 1.01 item 9.01

Myomo enters $5M common stock purchase agreement with Keystone Capital Partners

Up to $5M of common stock may be sold at Myomo's discretion; 50,000 commitment shares issued.
July 7, 2022, 7:59 PM ET earnings materiality 0.70 positive item 8.01 item 9.01

Myomo pre-announces Q2 revenue $3.4-3.6M, up 10-16% YoY; record pipeline adds

Preliminary Q2 2022 revenue $3.4–$3.6M, up 10–16% vs Q2 2021; all product revenue.
June 10, 2022, 7:59 PM ET other materiality 0.10 neutral item 5.07

Myomo shareholders elect Amy Knapp director and ratify Marcum as auditor

Amy Knapp elected as Class II director with 2,458,836 for, 352,291 withheld.

Executive changes

Appointed

Joseph M. Manko Jr.

Class I director

MYO · MYOMO, INC.

Effective: 2026-05-09
Filed: May 13, 2026, 4:10 PM ET

the Board appointed Joseph M. Manko Jr. to join the Board, effective on May 9, 2026.

Departed

Yitzchak Jacobovitz

Director

MYO · MYOMO, INC.

Filed: April 10, 2025, 7:59 PM ET

Also on April 4, 2025, Mr. Yitzchak Jacobovitz, a member of the Board and the Nominating and Corporate Governance Committee of the Board, informed the Company that he does not intend to stand for reelection at the Annual Meeting.

Departed

Amy Knapp

Director

MYO · MYOMO, INC.

Filed: April 10, 2025, 7:59 PM ET

On April 4, 2025, Ms. Amy Knapp, a member of the Board, the Audit Committee of the Board and the Nominating and Corporate Governance Committee of the Board, informed the Company that she does not intend to stand for reelection at the Company’s 2025 annual meeting of shareholders

Appointed

Heather Getz

Director

MYO · MYOMO, INC.

Effective: 2024-03-26
Filed: March 28, 2024, 7:59 PM ET

the Board increased its size from six to seven members and appointed Heather Getz to join the Board, effective on March 26, 2024.

Appointed

Yitzchak Jacobovitz

Class II Director

MYO · MYOMO, INC.

Effective: 2023-01-27
Filed: January 30, 2023, 6:59 PM ET

The board of directors increased the size of the Board from five to six members and appointed Yitzchak Jacobovitz, selected and nominated by AIGH, as a Class II director effective January 27, 2023

Earnings & guidance

2026-Q1 EPS reported -$0.07 vs consensus -$0.12 ▲ beat (+39.2%) filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.68 · Most common event earnings

21 positive 4 negative 25 neutral

source · MYO on sec.gov